Professional Documents
Culture Documents
ATOPIC DERMATITIS
(ATOPIC ECZEMA)
Donald Y. M. Leung, Lawrence F. Eichenfield, Mark Boguniewicz
Fitzpatricks Dermatology in General Medicine. 7th ed. New York:
McGraw-Hill Medical; 2008. P.146-58
Epidemiology
AD major public health problem
worldwide
Prevalence in children of 10-20%
Prevalence of AD in adults is
approximately 1-3%
The prevalence much lower in agricultural
countries
There is also a female preponderance,
with an overall female/male ratio of
2
1.3:1.0
Etiologi dan
Patogenesis
Peningkatan
respon
imunologik
Gangguan
barier kulit
Gangguan
sistem imun
alamiah
Chronic skin:
- hyperplastic epidermis
with elongation of the rete
ridges
- prominent hyperkeratosis
- minimal spongiosis
- surface IgE increased
Genetics
Filaggrin gene is found on chromosome
lq21
Variants in the SPINK5 gene influence the
balance of protease versus protease
inhibitor activity
Functional mutations in promoter region of
the C-C chemokines, RANTES and eotaxin.
Patogenesis
Disfungsi
sawar kulit
Abnormalitas
imunologik
Disregulasi
apoptosis
Peran
superantigen
stafilokokus
Clinical Findings
Typically begins during infancy. 50% by the first
year of life and 30% between the ages of 1-5
years.
50 -80% of AD patients develop allergic rhinitis
or asthma
later in chiJdhood.
Pruritus may be intermittent, but is usually worse
in the early evening and night.
9
Acute lesions
Intensely pruritic, erythematous papules,
excoriation, vesicles over erythematous skin, and
serous exudate
Subacute
lesions
erythematous, excoriated and scaling papules.
Chronic lesions
thickened plaques of skin, accentuated skin
markings (lichenification), and fibrotic papules
(prurigo nodularis
10
12
13
14
15
16
Laboratory Tests
Not needed in the routine evaluation.
Serum IgE levels are elevated in approximately 7080% patients but 20-30% have normal result.
Some of these patients may sensitive to microbial
antigens, as well some of these patients show positive
reactions using the atopy patch test.
The majority of patients with AD also have peripheral
blood eosinophilia and increased spontaneous
histamine release from basophils.
17
Diagnosis: based on
clinical findings by
Hanafin and Rajka
18
Should be considered
and ruled out before a
diagnosis of AD is made.
19
Complications
Ocular Problems
21
Hand Dermatitis
22
Topical Therapy
CUTANEOUS HYDRATION
TOPICAL CALCINEURIN
INHIBITORS
Tacrolimus ointment 0.03% has been approved for
intermittent treatment of moderate to severe AD in
children aged 2 years and older, with tacrolimus
ointment 0.1 percent approved for use in adults.
Pimecrolimus cream I percent is approved for
treatment of patients aged 2 years and older with mildmoderate AD.
Both drugs have proven to be effective with a good
safety profile for treaonent up to 4 years with
tacrolimus ointmencSl and up to 2 years with
pimecrolimus cream
24
25
27
Preparat Tar
Memiliki efek anti-pruritus dan antiinflamasi
Berguna utk menurunkan potensi
glukokortikoid topikal, ttp tdk boleh
digunakan utk kulit yg inflamasi. skin
Sampo Tar dapat berguna utk dermatitis
skalp
28
Fototerapi
Broadband UVB,
broadband UVA,
narrowband UVB (311
nm), UVA-I (340 to 400
nm), and kombinasi UVA-B
dpt berguna utk
tambahan terapi DA.
Fotokemoterapi dgn
psoralen dan sinar UVA
diindikasikan utk pasienpasien DA dgn lesi luas
atau berat.
Hospitalisasi
Pasien-pasien DA yg mjd eritroderma atau DA berat dan
resisten thd terapi rawat jalan hrs dihospitalisasi sebelum
mempertimbangkan terapi-terapi sistemik alternatif.
29
Terapi Sistemik
GLUKOKORTIKOID SISTEMIK
Jarang diindikasikan untuk pengobatan DA
kronik.
Glukokortikoid oral jangka pendek dpt
berguna utk eksaserbasi akut DA sementara
modalitas terapi lainnya diberikan.
Penting utk menurunkan dosis dan memulai
perawatan kulit secara intensif.
30
SIKLOSFORIN
Bekerja terutama pd sel-sel T dgn menekan
transkripsi sitokin.
Pengobatan siklosporin jangka pendek
bermanfaat utk anak-anak dan dewasa dgn DA
berat atau refrakter thd terapi konvensional.
Umumnya digunakan dosis 5 mg/kg BB efektif
utk pengobatan jangka pendek atau jangka
panjang (1 thn), beberapa penulis
menggunakan dosis 150 mg (dosis rendah) atau
300 mg (dosis tinggi) per hari siklosporin
mikroemulsi.
31
ANTIMETABOLIT
Open-label studies melaporkan mikrofenolat
mofetil jangka pendek, 2 g per hari, sebagai
monoterapi memberikan remisi lesi-lesi kulit pd
dewasa dgn DA resisten thd pengobatan lain.
Tetapi, hrs dihentikan jika pasien tdk berespon
dalam 4-8 minggu.
Metotreksat telah digunakan untuk pasien-pasien
DA dengan penyakit yg rekalsitran, meskipun
studi-studi terkontrol msh kurang.
Azatioprin telah digunakan utk DA berat,
meskipun belum ada percobaan-percobaan
terkontrol yg pernah melaporkan hal ini.
32
Terapi-terapi yg belum
terbukti
INTERFERON-
OMALIZUMAB
Anti-lgE monoklonal
kurang efektif untuk
pasien DA dewasa,
tetapi memberikan
perbaikan yg
signifikan pada
pasien-pasien DA
remaja.
33
IMUNOTERAPI
ALERGEN
Studi-studi terkontrol
Studi-studi terkontrol
msh diperlukan utk
msh diperlukan utk
menentukan peran
menentukan peran
imunoterapi thd penyakit
imunoterapi thd penyakit
ini.
ini.
PROBIOTIK
Pemberian probiotik
Pemberian probiotik
perinatal berupa strain GG
perinatal berupa strain GG
Lactobacillus rhamnosus
Lactobacillus rhamnosus
menunjukkan penurunan
menunjukkan penurunan
insiden DA pd anak yg
insiden DA pd anak yg
beresiko tinggi selama 2
beresiko tinggi selama 2
tahun pertama kehidupan.
tahun pertama kehidupan.
FOTOFERESIS
EKSTRAKORPOREA
L
Respon biasanya
Respon biasanya
bersifat temporer, dan
bersifat temporer, dan
efektifitasnya bisa
efektifitasnya bisa
hilang meskipun terapi
hilang meskipun terapi
dilanjutkan.
dilanjutkan.
34
35
TERIMA